Clinton, Mo. – (Dec. 7, 2020) – Golden Valley Memorial Healthcare (GVMH) is providing cutting-edge treatments for its COVID-19 patients to help them recover faster and avoid spending time in the hospital. These therapies include monoclonal antibodies, convalescent plasma and remdesivir.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight harmful viruses, such as COVID-19. This treatment is used in the outpatient setting to reduce COVID-19-related hospitalization and emergency room visits in high-risk patients.
Convalescent plasma therapy uses blood from people who have recovered from COVID-19. This blood contains antibodies, which are capable of fighting the virus and may help patients with COVID-19 improve faster. Convalescent plasma is provided to hospitalized patients.
GVMH is also providing remdesivir, an antiviral drug, to patients with COVID-19. Clinical research has shown that remdesivir has been successful in decreasing recovery time and improving outcomes in hospitalized patients with moderate to severe COVID-19.
“As a rural Missouri hospital, we are pleased to have been selected to provide these cutting-edge treatments to our patients to speed patient recovery and decrease hospital stays,” said Craig Thompson, CEO at GVMH.
